Connect Biopharma : INFORMATION CONTAINED IN THIS REPORT ON FORM 6 K Form 6 K
Document UNITED STATES SECURITIES...
Source: marketscreener.com
Regulus Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Regulus Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Regulus Therapeutics Today - Breaking & Trending Today
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration
Bio-Techne Corporation and Regulus Therapeutics Inc. announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients...
Source: marketscreener.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month […]
Source: tickerreport.com
Stock Analysts' New Coverage for April 8th (AACG, AAME, ADXS, AKTX, AMED, AMT, AP, APWC, ARTW, AVGR)
Stock Analysts’ new coverage for Monday, April 8th: StockNews.com began coverage on shares of ATA Creativity Global (NASDAQ:AACG). The firm issued a sell rating on the stock. StockNews.com began coverage on shares of Atlantic American (NASDAQ:AAME). The firm issued a hold rating on the stock. StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS). The […]
Source: wkrb13.com
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a report issued on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on RGLS. SVB Leerink assumed coverage on Regulus Therapeutics in a research report on Monday, March […]
Source: wkrb13.com